Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1058 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
21 Recruiting Arginase Inhibitor CB-1158 in Patients With Solid Tumors
Conditions: Metastatic Cancer;   Solid Tumors;   Non-small Cell Lung Cancer;   Colo-Rectal Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Squamous-cell Carcinomas of the Head and Neck
Interventions: Drug: CB-1158;   Drug: Nivolumab
22 Recruiting A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Conditions: Colorectal Cancer;   Triple Negative Breast Cancer;   Non-small Cell Lung Cancer (Adenocarcinoma)
Interventions: Biological: PDR001;   Biological: ACZ885;   Biological: CJM112;   Drug: TMT212;   Drug: EGF816
23 Not yet recruiting Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
24 Not yet recruiting A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Carcinoma;   NSCLC
Interventions: Drug: Ensartinib;   Drug: Durvalumab
25 Recruiting Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Conditions: Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Digestive System Neoplasms;   Endocrine Gland Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Lung Diseases;   Breast Neoplasms;   Breast Diseases;   Renal Neoplasm;   Solid Tumors
Interventions: Drug: Entinostat;   Other: Placebo
26 Not yet recruiting A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Conditions: Urinary Bladder Cancer;   Bladder Tumors;   Transitional Cell Carcinoma of the Bladder;   Malignant Melanoma;   Melanoma;   Skin Cancer;   Carcinoma, Non-Small-Cell Lung;   Lung Cancer
Interventions: Biological: NEO-PV-01;   Biological: Nivolumab;   Other: Adjuvant
27 Not yet recruiting Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Conditions: Solid Neoplasm;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Sarcoma;   Colorectal Cancer;   Head and Neck Cancer;   Cancer of Unknown Primary;   Bladder Cancer;   Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Drug: Palbociclib
28 Recruiting First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: PLB1001
29 Not yet recruiting Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer
Condition: Stage I NSCLC
Intervention: Other: microwave ablation
30 Not yet recruiting Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
31 Recruiting Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)
Condition: Stage IV EGFR Mutated Non-Small Cell Lung Cancer
Interventions: Radiation: Radiation: SBRT;   Drug: TKI (Gefitinib or Tarceva )
32 Not yet recruiting A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Conditions: Colorectal Cancer;   Non-small Cell Lung Carcinoma (Adenocarcinoma);   Triple Negative Breast Cancer
Interventions: Biological: PDR001;   Drug: LCL161;   Drug: Everolimus;   Drug: Panobinostat
33 Recruiting Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Condition: Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine/Carboplatin;   Drug: Gemcitabine/Cisplatin;   Drug: Docetaxel/Oxaliplatin;   Drug: Docetaxel/Carboplatin;   Drug: Placebo
34 Not yet recruiting Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Conditions: Recurrent Colorectal Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Biological: Tremelimumab
35 Not yet recruiting Pulmonary Rehabilitation Before Lung Cancer Resection
Conditions: Non-small Cell Lung Cancer (NSCLC);   Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Other: education;   Procedure: rehabilitation;   Device: pedometer;   Procedure: surgery
36 Recruiting A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors
Conditions: Hepatocellular Carcinoma;   Renal Cell Carcinoma;   Bladder Cancer;   Colorectal Cancer;   Non-small-cell Lung Cancer;   Breast Cancer
Intervention: Biological: D-CIK and anti-PD-1 antibody
37 Not yet recruiting SIMT Stereotactic Radiosurgery Outcomes Study
Conditions: Brain Metastases;   Breast Cancer;   Non Small Cell Lung Cancer;   Gastrointestinal Cancer;   Renal Cell Cancer;   Melanoma
Intervention: Radiation: Stereotactic radiosurgery
38 Recruiting An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
Conditions: Advanced Solid Tumor;   Non-Small Cell Lung Cancer
Interventions: Drug: PT-112;   Drug: Docetaxel
39 Not yet recruiting Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
Condition: Small Cell Carcinoma
Interventions: Drug: Nortriptyline Hydrochloride;   Drug: Paclitaxel
40 Not yet recruiting Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
Conditions: Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years